Page 1

Interim Report April - June 2021 ( SEK million ) Net sales Sales growth % Gross margin % EBIT Profit for the period A quarter characterized by solid sales growth , partly due to Covid tests April - June The Group's sales during the first quarter amounted to SEK 37.3 ( 99.5 ) million . Adjusted for non - recurring sales , sales amounted to SEK 32.3 ( 22.5 ) million , an increase of 44 % . Gross profit amounted to SEK 16.0 ( 22.4 ) million for the quarter , an increase of 28.3 % . Operating profit for the quarter amounted to SEK 3 ( 11.6 ) million . Earnings per share were SEK 0:09 ( 0:39 ) for the quarter . Cash flow from operating activities amounted to SEK -15.4 ( 54.5 ) million for the quarter . Cash and cash equivalents were SEK 17.8 ( 64.8 ) million at the end of the quarter . April - June 2021 37,29 -63 43 3,04 2,51 EQL PHARMA April - June 2020 99,51 588 22 11,58 11,21 April - March 2021 179,14 149 28 11,52 10,37